On Built-in Test Classes for Object-Oriented and Component-Based Information Systems

Yingxu Wang,Shushma Patel,D. Patel

DOI: https://doi.org/10.1007/978-1-4471-0719-4_32

Abstract:

What problem does this paper attempt to address?

Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review)

Xing Huang,Mao Li,Shengzhong Hou,Bole Tian

DOI: https://doi.org/10.3892/ijo.2021.5281

2021-01-01

International Journal of Oncology

Abstract:A large body of evidence has revealed that the microbiome serves a role in all aspects of cancer, particularly cancer treatment. To date, studies investigating the relationship between the microbiome and systemic therapy for pancreatic ductal adenocarcinoma (PDAC) are lacking. PDAC is a high-mortality malignancy (5-year survival rate; <9% for all stages). Systemic therapy is one of the most important treatment choices for all patients; however, resistance or toxicity can affect its efficacy. Studies have supported the hypothesis that the microbiome is closely associated with the response to systemic therapy in PDAC, including the induction of drug resistance, or toxicity and therapy-related changes in microbiota composition. The present review comprehensively summarized the role of the microbiome in systemic therapy for PDAC and the associated molecular mechanisms in an attempt to provide a novel direction for the improvement of treatment response and proposed potential directions for in-depth research.
Microbiota Regulates Pancreatic Cancer Carcinogenesis through Altered Immune Response.

Yihan Chai,Zhengze Huang,Xuqiu Shen,Tianyu Lin,Yiyin Zhang,Xu Feng,Qijiang Mao,Yuelong Liang

DOI: https://doi.org/10.3390/microorganisms11051240

IF: 4.5

2023-01-01

Microorganisms

Abstract:The microbiota is present in many parts of the human body and plays essential roles. The most typical case is the occurrence and development of cancer. Pancreatic cancer (PC), one of the most aggressive and lethal types of cancer, has recently attracted the attention of researchers. Recent research has revealed that the microbiota regulates PC carcinogenesis via an altered immune response. Specifically, the microbiota, in several sites, including the oral cavity, gastrointestinal tract, and pancreatic tissue, along with the numerous small molecules and metabolites it produces, influences cancer progression and treatment by activating oncogenic signaling, enhancing oncogenic metabolic pathways, altering cancer cell proliferation, and triggering chronic inflammation that suppresses tumor immunity. Diagnostics and treatments based on or in combination with the microbiota offer novel insights to improve efficiency compared with existing therapies.
Prognostic Effects of the Gastric Mucosal Microbiota in Gastric Cancer

Jinpu Yang,Jiaren Xu,Zongxin Ling,Xinxin Zhou,Yongqiang Si,Xiaosun Liu,Feng Ji

DOI: https://doi.org/10.1111/cas.15661

IF: 5.7

2022-01-01

Cancer Science

Abstract:Gastric cancer (GC) is one of the most common malignant tumors with a high incidence and mortality. Microbiota play a significant role in human health and disease. We aimed to investigate the prognostic value of the gastric microbiota in different stomach microhabitats. We used our previously published 16S rRNA gene sequence data. We retrospectively enrolled a cohort of 132 patients with GC with complete prognostic information and selected 78 normal tissues, 49 peritumoral tissues, and 112 tumoral tissues for microbiota analysis. Patients with different prognoses showed different gastric microbiota compositions and diversity. The association network of the abundant gastric microbiota was more complicated in patients with poor prognoses. In the peritumoral microhabitat of patients with good prognoses, Helicobacter was significantly increased, whereas Halomonas and Shewanella were significantly decreased relative to that in the peritumoral microhabitat of patients with poor prognoses. PiCRUSt analysis revealed that the peritumoral microbiota had more different Kyoto Encyclopedia of Genes and Genomes pathways than did the tumoral and normal microbiota. This study evaluated the long-term prognostic value of the gastric mucosal microbiota in patients with GC. These findings suggested that the characteristic alterations of the gastric mucosal microbiota may be markers for clinical outcomes in these patients.
Intratumoral microbiota of pancreatic ductal adenocarcinoma impact patient prognosis by influencing tumor microenvironment

Jingze Leng,Hengyi Xu,Xiaoyu Liu,Yufan Yang,Chun Ning,Lejia Sun,Jiangming Qu,Xindi Ke,Xun Lan

DOI: https://doi.org/10.1007/s12672-024-01320-6

2024-09-13

Abstract:Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly metastatic potential and a heterogeneous tumor microenvironment. It exhibits limited sensitivity to conventional therapies, necessitating a deeper understanding of its pathogenesis. The role of the intratumoral microbiome in regulating cancer development in PDAC has been the subject of debate. Previous investigations into intra-tumor microbiomes have yielded uncertain results due to sample size limitations and insufficient decontamination procedures. Further research is imperative to elucidate the intricate relationship between intra-tumor microbiomes, the immune landscape of PDAC, and overall prognosis. Results: Our findings revealed that the intratumor microbiota in PDAC tissue exhibited lower diversity and distinct communities compared to non-tumor tissues. The top microorganisms distinguishing between patients with long or short survival were used to construct the risk signature. We found that Stenotrophomonas is implicated in short survival of PDAC patients, while Neorickettia and Mediterraneibacter are correlated with long survival. This microbiome-based PDAC subtyping, grounded in prognosis-related signatures, exhibited significant correlations with distinct clinical prognoses and immune microenvironments. Microorganisms associated with negative prognoses were linked to pro-tumor immune activation, while those associated with positive prognoses were linked to anti-tumor immune response activation and a more favorable prognosis. Conclusions: Our PDAC subtyping approach, based on a microbiome-derived prognostic risk signature, unveiled compelling associations between the PDAC microbiota and disparities in both clinical prognosis and the tumor microenvironment. These findings suggest that microbiota may serve as a promising biomarker for predicting the prognosis of PDAC.
21st century health services challenges for an ageing population.

M. Lakhani

DOI: https://doi.org/10.3399/bjgp12X656739

2012-10-01

Abstract:Advance care planning should be added to Oliver’s 10 challenges for general practice for an ageing population.1 Many of the scenarios he describes, such as, multiple conditions, dementia, and repeated hospitalisation, are in fact prognostic markers for end-of-life care. Prognostic indicator guidance …
The correlation between gut and intra-tumor microbiota and PDAC: Etiology, diagnostics and therapeutics

Jiwei Qian,Xin Zhang,Butian Wei,Zhe Tang,Bo Zhang

DOI: https://doi.org/10.1016/j.bbcan.2023.188943

Abstract:Pancreatic ductal adenocarcinoma (PDAC) is one of the lethal cancers in the world and its 5-year survival rate is <10%. Due to the unique TME and dense tissue structure, its curative efficacy is far from satisfactory，the immunotherapy is even more invalid. According to the recent studies, the gut and tumor microbiota have been proved to play a key role in the development, progression and prognosis of PDAC. Based on the differences of microbiome composition observed in PDAC patients and normal pancreas, many researches have been made focusing on the latent communication between gut and intra-tumor microbiota and PDAC. In this review, we will demonstrate the potential mechanism of the oncogenic effects of GM and IM and their crucial effects on modulating the TME. Besides, we focus on their interaction with chemotherapeutic and immunotherapeutic drugs and inducing the drug resistance, thus enlightening the promising role to be used to monitor the occurrence of PDAC, accurately modulate the immune environment to promote the therapeutic efficacy and predict the prognosis.
The Impact of Health Care Financing on Family Budgets

E. Rasell,J. Bernstein,Kainan Tang

DOI: https://doi.org/10.2190/MM38-P4HV-2W32-4KYR

1993-11-01

International Journal of Health Services

Abstract:Although businesses, federal and state governments, and insurance companies are major funding sources for health care, they are just intermediate sources. Ultimately, individuals and families pay all health care costs through out-of-pocket spending, insurance premiums, or federal, state, and local taxes. Using a microsimulation model with data from the 1987 National Medical Expenditure Survey, the Internal Revenue Service's Individual Tax Model, and the Consumer Expenditure Survey, the authors examine the distribution of health care spending, by decile, among families and individuals. They find that the distribution of health expenditures is very regressive, with low-income families paying twice the share of income paid by high-income families. The distribution of out-of-pocket expenditures, which comprise 24 percent of total spending, is the most regressive, with low-income families paying 8.5 times the share of income paid by high-income families. Spending on premiums is also regressive, and the regressivity would increase if everyone had private insurance. Expenditures through the public sector are progressive. Regressivity is greater among the elderly than the nonelderly. Out-of-pocket expenditures account for 41 percent of all health care spending by the elderly. A more equitably financed health care system would increase the share of funding raised through progressive taxes, and decrease reliance on expenditures made out of pocket and on premiums.
Intratumor Microbiome Analysis Identifies Positive Association Between Megasphaera and Survival of Chinese Patients With Pancreatic Ductal Adenocarcinomas

Yu Huang,Ning Zhu,Xing Zheng,Yanhong Liu,Haopeng Lu,Xiaochen Yin,Huaijie Hao,Yan Tan,Dongjie Wang,Han Hu,Yong Liang,Xinxing Li,Zhiqian Hu,Yiming Yin

DOI: https://doi.org/10.3389/fimmu.2022.785422

IF: 7.3

2022-01-25

Frontiers in Immunology

Abstract:Human tumors harbor a plethora of microbiota. It has been shown that the composition and diversity of intratumor microbiome are significantly associated with the survival of patients with pancreatic ductal adenocarcinoma (PDAC). However, the association in Chinese patients as well as the effect of different microorganisms on inhibiting tumor growth are unclear. In this study, we collected tumor samples resected from long-term and short-term PDAC survivors and performed 16S rRNA amplicon sequencing. We found that the microbiome in samples with different survival time were significantly different, and the differential bacterial composition was associated with the metabolic pathways in the tumor microenvironment. Furthermore, administration of Megasphaera , one of the differential bacteria, induced a better tumor growth inhibition effect when combined with the immune checkpoint inhibitor anti-programmed cell death-1 (anti-PD-1) treatment in mice bearing 4T1 tumor. These results indicate that specific intratumor microbiome can enhance the anti-tumor effect in the host, laying a foundation for further clarifying the underlying detailed mechanism.

immunology
The Microbiota and Microbiome in Pancreatic Cancer: More Influential Than Expected

Weiwei Miao,Si Shi,Chen Liang,Qing-Cai Meng,Jie Hua,Yi-Yin Zhang,Jiang Liu,Bo Zhang,Jin Xu,Lei Yu

DOI: https://doi.org/10.1186/s12943-019-1008-0

IF: 37.3

2019-01-01

Molecular Cancer

Abstract:Microbiota is just beginning to be recognized as an important player in carcinogenesis and the interplay among microbes is greater than expected. Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease for which mortality closely parallels incidence. Early detection would provide the best opportunity to increase survival rates. Specific well-studied oral, gastrointestinal, and intrapancreatic microbes and some kinds of hepatotropic viruses and bactibilia may have potential etiological roles in pancreatic carcinogenesis, or modulating individual responses to oncotherapy. Concrete mechanisms mainly involve perpetuating inflammation, regulating the immune system-microbe-tumor axis, affecting metabolism, and altering the tumor microenvironment. The revolutionary technology of omics has generated insight into cancer microbiomes. A better understanding of the microbiota in PDAC might lead to the establishment of screening or early-stage diagnosis methods, implementation of cancer bacteriotherapy, adjustment of therapeutic efficacy even alleviating the adverse effects, creating new opportunities and fostering hope for desperate PDAC patients.
Alterations of Gastric Mucosal Microbiota Across Different Stomach Microhabitats in a Cohort of 276 Patients with Gastric Cancer

Xiaosun Liu,Li Shao,Xia Liu,Feng Ji,Ying Mei,Yiwen Cheng,Fengping Liu,Chongxian Yan,Lanjuan Li,Zongxin Ling

DOI: https://doi.org/10.1016/j.ebiom.2018.12.034

2018-01-01

SSRN Electronic Journal

Abstract:BACKGROUND:As part of the tumor microenvironment, the gastric microbiota play vital roles in tumor initiation, progression and metastasis, but stomach microhabitats are not always uniform. We aimed to characterize differences of gastric microbiota in stomach microhabitats associated with gastric cancer (GC) development.METHODS:A cohort of 276 GC patients without preoperative chemotherapy was enrolled retrospectively, and 230 normal, 247 peritumoral and 229 tumoral tissues were obtained for gastric microbiota analysis targeting the 16S rRNA gene by MiSeq sequencing. The microbial diversity and composition, bacterial co-occurrence correlations and predictive functional profiles were compared across different microhabitats.FINDINGS:GC-specific stomach microhabitats, not GC stages or types, determine the composition and diversity of the gastric microbiota. Most notably, bacterial richness was decreased in peritumoral and tumoral microhabitats, and the correlation network of abundant gastric bacteria was simplified in tumoral microhabitat. Helicobacter pylori (HP), Prevotella copri and Bacteroides uniformis were significantly decreased, whereas Prevotella melaninogenica, Streptococcus anginosus and Propionibacterium acnes were increased in tumoral microhabitat. Higher HP colonisation influenced the overall structure of the gastric microbiota in normal and peritumoral microhabitats. PiCRUSt analysis revealed that genes associated with nucleotide transport and metabolism and amino acid transport and metabolism were significantly enriched in tumoral microbiota, while gastric acid secretion was significantly higher in HP positive group of the tumoral microbiota.INTERPRETATION:Our present study provided new insights into the roles of gastric microbiota in different stomach microhabitats in gastric carcinogenesis, especially the pathogenesis of HP. FUND: National Natural Science Foundation of China.
Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review

Chengliang Huang,Meizhang Li,Ben Liu,Huanbo Zhu,Qun Dai,Xianming Fan,Kathan Mehta,Chao Huang,Prakash Neupane,Fen Wang,Weijing Sun,Shahid Umar,Cuncong Zhong,Jun Zhang

DOI: https://doi.org/10.3389/fonc.2021.642110

IF: 4.7

2021-01-01

Frontiers in Oncology

Abstract:Background: Gut microbiome is proved to affect the activity of immunotherapy in certain tumors. However, little is known if there is universal impact on both the treatment response and adverse effects (AEs) of immune checkpoint inhibitors (ICIs) across multiple solid tumors, and whether such impact can be modulated by common gut microbiome modifiers, such as antibiotics and diet. Methods: A systematic search in PubMed followed by stringent manual review were performed to identify clinical cohort studies that evaluated the relevance of gut microbiome to ICIs (response and/or AEs, 12 studies), or association of antibiotics with ICIs (17 studies), or impact of diet on gut microbiome (16 studies). Only original studies published in English before April 1st, 2020 were used. Qualified studies identified in the reference were also included. Results: At the phylum level, patients who had enriched abundance in Firmicutes and Verrucomicrobia almost universally had better response from ICIs, whereas those who were enriched in Proteobacteria universally presented with unfavorable outcome. Mixed correlations were observed for Bacteroidetes in relating to treatment response. Regarding the AEs, Firmicutes correlated to higher incidence whereas Bacteroidetes were clearly associated with less occurrence. Interestingly, across various solid tumors, majority of the studies suggested a negative association of antibiotic use with clinical response from ICIs, especially within 1-2 month prior to the initiation of ICIs. Finally, we observed a significant correlation of plant-based diet in relating to the enrichment of “ICI-favoring” gut microbiome (P = 0.0476). Conclusions: Gut microbiome may serve as a novel modifiable biomarker for both the treatment response and AEs of ICIs across various solid tumors. Further study is needed to understand the underlying mechanism, minimize the negative impact of antibiotics on ICIs, and gain insight regarding the role of diet so that this important lifestyle factor can be harnessed to improve the therapeutic outcomes of cancer immunotherapy partly through its impact on gut microbiome.
Alterations of the bile microbiome is associated with progression-free survival in pancreatic ductal adenocarcinoma patients

Hang Jiang,Yitong Tian,Linwei Xu,Xing Chen,Yurun Huang,Jia Wu,Tingzhang Wang,Tingting Liu,Xitian Wu,Chao Ye,Hao Wu,Wenkai Ye,Luo Fang,Yuhua Zhang

DOI: https://doi.org/10.1186/s12866-024-03371-9

IF: 4.465

2024-07-01

BMC Microbiology

Abstract:Abstract Background Patients with pancreatic ductal adenocarcinoma (PDAC) display an altered oral, gastrointestinal, and intra-pancreatic microbiome compared to healthy individuals. However, knowledge regarding the bile microbiome and its potential impact on progression-free survival in PDACs remains limited. Methods Patients with PDAC ( n = 45), including 20 matched pairs before and after surgery, and benign controls ( n = 16) were included prospectively. The characteristics of the microbiomes of the total 81 bile were revealed by 16 S-rRNA gene sequencing. PDAC patients were divided into distinct groups based on tumor marker levels, disease staging, before and after surgery, as well as progression free survival (PFS) for further analysis. Disease diagnostic model was formulated utilizing the random forest algorithm. Results PDAC patients harbor a unique and diverse bile microbiome (PCoA, weighted Unifrac, p = 0.038), and the increasing microbial diversity is correlated with dysbiosis according to key microbes and microbial functions. Aliihoeflea emerged as the genus displaying the most significant alteration among two groups ( p < 0.01). Significant differences were found in beta diversity of the bile microbiome between long-term PFS and short-term PFS groups (PCoA, weighted Unifrac, p = 0.005). Bacillota and Actinomycetota were identified as altered phylum between two groups associated with progression-free survival in all PDAC patients. Additionally, we identified three biomarkers as the most suitable set for the random forest model, which indicated a significantly elevated likelihood of disease occurrence in the PDAC group ( p < 0.0001). The area under the receiver operating characteristic (ROC) curve reached 80.8% with a 95% confidence interval ranging from 55.0 to 100%. Due to the scarcity of bile samples, we were unable to conduct further external verification. Conclusion PDAC is characterized by an altered microbiome of bile ducts. Biliary dysbiosis is linked with progression-free survival in all PDACs. This study revealed the alteration of the bile microbiome in PDACs and successfully developed a diagnostic model for PDAC.

microbiology
Current status and prospect of gut and oral microbiome in pancreatic cancer: Clinical and translational perspectives

Pengyu Li,Hanyu Zhang,Menghua Dai

DOI: https://doi.org/10.1016/j.canlet.2024.217274

2024-11-01

Abstract:Pancreatic cancer is a highly lethal malignancy, and its diagnosis and treatment continue to pose significant challenges. Despite advancements in surgical and comprehensive treatment methods, the five-year survival rate remains below 12 %. With the rapid development of microbiome science, the gut and oral microbiota, which are readily accessible and can be sampled non-invasively, have emerged as a novel area of interest in pancreatic cancer research. Dysbiosis in these microbial communities can induce persistent inflammatory responses and affect the host's immune system, promoting cancer development and impacting the efficacy of treatments like chemotherapy and immunotherapy. This review provides an up-to-date overview of the roles of both gut and oral microbiota in the onset, progression, diagnosis, and treatment of pancreatic cancer. It analyzes the potential of utilizing these microbiomes as biomarkers and therapeutic targets from a clinical application perspective. Furthermore, it discusses future research directions aimed at harnessing these insights to advance the diagnosis and treatment strategies for pancreatic cancer. By focusing on the microbiome's role in clinical and translational medicine, this review offers insights into improving pancreatic cancer diagnosis and treatment outcomes.
Research Progress of Pancreas-Related Microorganisms and Pancreatic Cancer

Wenqing Zhang,Kunpeng Zhang,Peng Zhang,Juanjuan Zheng,Congcong Min,Xiaoyu Li

DOI: https://doi.org/10.3389/fonc.2020.604531

IF: 4.7

2021-01-14

Frontiers in Oncology

Abstract:Pancreatic cancer is one of the most common digestive system cancers. Early diagnosis is difficult owing to the lack of specific symptoms and reliable biomarkers. The cause of pancreatic cancer remains ambiguous. Smoking, drinking, new-onset diabetes, and chronic pancreatitis have been proven to be associated with the occurrence of pancreatic cancer. In recent years, a large number of studies have clarified that a variety of microorganisms colonized in pancreatic cancer tissues are also closely related to the occurrence and development of pancreatic cancer, and the specific mechanisms include inflammatory induction, immune regulation, metabolism, and microenvironment changes caused by microorganism. The mechanism of action of the pancreatic colonized microbiome in the tumor microenvironment, as well as immunotherapy approaches require further study in order to find more evidence to explain the complex relationship between the pancreatic colonized microbiome and PDAC. Relevant studies targeting the microbiome may provide insight into the mechanisms of PDAC development and progression, improving treatment effectiveness and overall patient prognosis. In this article, we focus on the research relating to the microorganisms colonized in pancreatic cancer tissues, including viruses, bacteria, and fungi. We also highlight the microbial diversity in the occurrence, invasion, metastasis, treatment, and prognosis of pancreatic cancer in order to elucidate its significance in the early diagnosis and new therapeutic treatment of pancreatic cancer, which urgently need to be improved in clinical practice. The elimination or increase in diversity of the pancreatic microbiome is beneficial for prolonging the survival of PDAC patients, improving the response to chemotherapy drugs, and reducing tumor burden. The colonization of microorganisms in the pancreas may become a new hotspot in the diagnosis and treatment of pancreatic cancer.

oncology
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes

Erick Riquelme,Yu Zhang,Liangliang Zhang,Maria Montiel,Michelle Zoltan,Wenli Dong,Pompeyo Quesada,Ismet Sahin,Vidhi Chandra,Anthony San Lucas,Paul Scheet,Hanwen Xu,Samir M. Hanash,Lei Feng,Jared K. Burks,Kim-Anh Do,Christine B. Peterson,Deborah Nejman,Ching-Wei D. Tzeng,Michael P. Kim,Cynthia L. Sears,Nadim Ajami,Joseph Petrosino,Laura D. Wood,Anirban Maitra,Ravid Straussman,Matthew Katz,James Robert White,Robert Jenq,Jennifer Wargo,Florencia McAllister

DOI: https://doi.org/10.1016/j.cell.2019.07.008

IF: 64.5

2019-08-01

Cell

Abstract:Most patients diagnosed with resected pancreatic adenocarcinoma (PDAC) survive less than 5 years, but a minor subset survives longer. Here, we dissect the role of the tumor microbiota and the immune system in influencing long-term survival. Using 16S rRNA gene sequencing, we analyzed the tumor microbiome composition in PDAC patients with short-term survival (STS) and long-term survival (LTS). We found higher alpha-diversity in the tumor microbiome of LTS patients and identified an intra-tumoral microbiome signature ( Pseudoxanthomonas- Streptomyces- Saccharopolyspora- Bacillus clausii) highly predictive of long-term survivorship in both discovery and validation cohorts. Through human-into-mice fecal microbiota transplantation (FMT) experiments from STS, LTS, or control donors, we were able to differentially modulate the tumor microbiome and affect tumor growth as well as tumor immune infiltration. Our study demonstrates that PDAC microbiome composition, which cross-talks to the gut microbiome, influences the host immune response and natural history of the disease.

cell biology,biochemistry & molecular biology
Abstract 2178: Metagenomic analysis unveils the microbial landscape of pancreatic tumors

Sheema Khan,Goutam Banerjee,Saini Setua,Anupam Dhasmana,Pratik Banerjee,Murali Mohan Yallapu,Stephen W. Behrman,Subhash Chauhan,Daleniece Higgins Jones,Bhavin Chauhan

DOI: https://doi.org/10.1158/1538-7445.am2024-2178

IF: 11.2

2024-03-23

Cancer Research

Abstract:The composition of resident microbes in the human body is linked to various diseases and their treatment outcomes. Although studies have identified pancreatic ductal adenocarcinoma (PDAC) associated bacterial communities in the oral and gut samples, herein we hypothesize the prevalence of microbiota in pancreatic tumor tissues is different as compared to their matched adjacent, histologically normal appearing tissues and these microbial molecular signatures can be highly useful for PDAC diagnosis/prognosis. In this study, we performed comparative profiling of bacterial populations in pancreatic tumors and their respective adjacent normal tissues using 16S rRNA-based metagenomics analysis. This study revealed a higher abundance of Proteobacteria and Actinomycetota in tumor tissues compared to adjacent normal tissues. Interestingly, the Linear Discriminant Analysis (LDA) scores unambiguously revealed an enrichment of Delftia in tumor tissues, whereas Sphingomonas, Streptococcus, and Citrobacter exhibited depletion in tumor tissues. Furthermore, we analyzed the microbial composition between different groups of patients with different tumor differentiation stages. The bacterial genera, Delftia and Staphylococcus were very high in G1 stages (well differentiated) compared to G2 (well to moderate/moderately differentiated) and G3/G4 (poorly differentiated). However, the abundance of Actinobacter and Cloacibacterium was found to be very high in G2 and G3, respectively. Additionally, we evaluated the correlation of PD-L1 expression with the abundance of bacterial genera in tumor lesions. Our results indicated that three genus such as Streptomyces, Cutibacterium, and Delftia have a positive correlation with PD-L1 expression. Collectively, these findings demonstrate that PDAC lesions harbor relatively different microbiota compared to their normal tumor-adjacent tissues, and this information might be helpful for the diagnosis and prognosis of PADC patients. Citation Format: Sheema Khan, Goutam Banerjee, Saini Setua, Anupam Dhasmana, Pratik Banerjee, Murali Mohan Yallapu, Stephen W. Behrman, Subhash Chauhan, Daleniece Higgins Jones, Bhavin Chauhan. Metagenomic analysis unveils the microbial landscape of pancreatic tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2178.

oncology
Gut Microbial Profile in Patients with Pancreatic Cancer

Xue-Yuan Wang,Zao-Xi Sun,Emmanuel Costantine Makale,Zheng-Ke Sun,Tai-Cheng Wang,Zhi-Ying Hou,Xing-Yue Yu,Wenfang Long,Guan-Kui Du,Hairong Huang

DOI: https://doi.org/10.5812/jjm-122386

2022-06-21

Jundishapur Journal of Microbiology

Abstract:Background: Pancreatic cancer is a lethal tumor with a poor prognosis. The connection between pancreatic cancer and gut microbiota is less reported. Objectives: This study analyzed microbial characteristics in patients with pancreatic cancer from the tropical area of China and explored the potential impact of the characteristic microflora on pancreatic cancer. Methods: Stool samples and blood test indices of participants were collected in Hainan, China. Metagenomic sequencing was used to analyze the gut microbiota characteristics. The R corrplot package was used to analyze the correlation between gut microbiota and blood test indices. Results: The microbial community in pancreatic cancer were clustered together and significantly separated from controls. The Simpson index was increased significantly in pancreatic cancer compared to controls. The abundances of butyrate-producing bacteria (Anaerostipes hadrus, Lachnoclostridium phocaeense, and Romboutsia ilealis), Bifidobacteria, and [Eubacterium] eligens were significantly decreased, while Fusobacterium, Enterobacter, and Enterococcus were significantly increased in pancreatic cancer. Prevotella copri may have a vital role in the bacterial interaction network. Pathways connected to metabolism, environment (bacterial secretion system), genetic information (protein export and ribosome), and human diseases (infectious diseases and drug resistance) were increased in the pancreatic cancer group. Butyrate-producing bacteria (butyrate-producing bacterium SS3/4, A. hadrus, R. intestinalis, and Faecalibacterium prausnitzii) and Bifidobacteria were significantly negatively correlated with the neutrophil-to-lymphocyte ratio. Conclusions: The gut microbiome was distinct in patients with pancreatic cancer from the tropical area of China. Changes in intestinal flora abundance and metabolic pathways may play an essential role in the occurrence and development of pancreatic cancer.

microbiology
Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma

Shohei Abe,Atsuhiro Masuda,Tomonori Matsumoto,Jun Inoue,Hirochika Toyama,Arata Sakai,Takashi Kobayashi,Takeshi Tanaka,Masahiro Tsujimae,Kohei Yamakawa,Masanori Gonda,Shigeto Masuda,Hisahiro Uemura,Shinya Kohashi,Noriko Inomata,Kae Nagao,Yoshiyuki Harada,Mika Miki,Yosuke Irie,Noriko Juri,Testuhisa Ko,Yusuke Yokotani,Yuki Oka,Shogo Ota,Maki Kanzawa,Tomoo Itoh,Toshio Imai,Takumi Fukumoto,Eiji Hara,Yuzo Kodama

DOI: https://doi.org/10.1007/s00535-023-02069-5

2024-01-21

Journal of Gastroenterology

Abstract:Recent evidence suggests that the presence of microbiome within human pancreatic ductal adenocarcinoma (PDAC) tissue potentially influences cancer progression and prognosis. However, the significance of tumor-resident microbiome remains unclear. We aimed to elucidate the impact of intratumoral bacteria on the pathophysiology and prognosis of human PDAC.

gastroenterology & hepatology
Modulating effect of thiol-disulfide status on [14C]aminopyrine accumulation in the isolated parietal cell.

C. Olson,A. Soll,N. Kaplowitz

DOI: https://doi.org/10.1016/s0021-9258(17)39557-1

IF: 5.485

1985-07-05

Journal of Biological Chemistry

Abstract:
Secure Hamming distance based record linkage with malicious adversaries

Bo Zhang,Rong Cheng,Fangguo Zhang

DOI: https://doi.org/10.1016/j.compeleceng.2013.07.008

IF: 4.152

2014-08-01

Computers & Electrical Engineering

Abstract:

On Built-in Test Classes for Object-Oriented and Component-Based Information Systems

Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review)

Microbiota Regulates Pancreatic Cancer Carcinogenesis through Altered Immune Response.

Prognostic Effects of the Gastric Mucosal Microbiota in Gastric Cancer

Intratumoral microbiota of pancreatic ductal adenocarcinoma impact patient prognosis by influencing tumor microenvironment

21st century health services challenges for an ageing population.

The correlation between gut and intra-tumor microbiota and PDAC: Etiology, diagnostics and therapeutics

The Impact of Health Care Financing on Family Budgets

Intratumor Microbiome Analysis Identifies Positive Association Between Megasphaera and Survival of Chinese Patients With Pancreatic Ductal Adenocarcinomas

The Microbiota and Microbiome in Pancreatic Cancer: More Influential Than Expected

Alterations of Gastric Mucosal Microbiota Across Different Stomach Microhabitats in a Cohort of 276 Patients with Gastric Cancer

Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review

Alterations of the bile microbiome is associated with progression-free survival in pancreatic ductal adenocarcinoma patients

Current status and prospect of gut and oral microbiome in pancreatic cancer: Clinical and translational perspectives

Research Progress of Pancreas-Related Microorganisms and Pancreatic Cancer

Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes

Abstract 2178: Metagenomic analysis unveils the microbial landscape of pancreatic tumors

Gut Microbial Profile in Patients with Pancreatic Cancer

Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma

Modulating effect of thiol-disulfide status on [14C]aminopyrine accumulation in the isolated parietal cell.

Secure Hamming distance based record linkage with malicious adversaries